Shares of AIM ImmunoTech (AIM) cratered 83.7% in a single session, plunging from $2.79 to $0.45, after the company announced a deeply discounted capital raise that flooded the market with new shares and signaled acute financial distress. For a micro-cap biotech already struggling to advance its drug pipeline, the move raises existential questions about whether existing shareholders have anything left to salvage. AIM ImmunoTech's Desperation Financing Torches 84% of Shareholder Value — Is This a Lifeline or a Death Spiral?
Shares of AIM ImmunoTech collapsed 83.7% to $0.45 after the micro-cap biotech disclosed a punishingly dilutive capital raise that priced new shares at a fraction of the prior close. The deal exposes a company running on fumes with a stock exchange deadline just hours away, leaving shareholders to wonder whether survival itself is a realistic outcome.
The Discount Screams Desperation, Not Strategy. AIM entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market for gross proceeds of approximately $2.65 million.
The company will issue 2,554,119 shares at just $0.5189 per share — an 81% discount to the June 9 close of $2.79. The concurrent private placement adds an equal number of unregistered shares plus Class J warrants to purchase up to 10,216,476 additional shares. That means investors who held stock at $2.79 now face a potential flood of over 15 million new shares entering a market that previously had far fewer outstanding — a textbook dilution catastrophe.
The Warrant Overhang Could Crush the Stock for Years. The Class J warrants carry an exercise price of $0.5189, require stockholder approval, and expire five years from the initial exercise date. This isn't the first round: in May, the company raised roughly $4.2 million through a warrant exercise, issuing replacement warrants for up to 17.4 million shares at $0.60. Each successive deal prices lower, creating a downward spiral where new financing anchors the stock at ever-cheaper levels.
The NYSE Is Watching — and the Clock Has Run Out. AIM disclosed a stockholders' deficit of approximately $9.78 million as of December 31, 2025, and faces potential delisting if it cannot raise equity above $6 million by June 11, 2026.
The company projected it would have at least $6 million in stockholders' equity after its May offering closed. This latest raise appears designed to clear that bar by tomorrow's deadline — barely.
$2.65 Million Barely Buys Time. AIM burned through roughly $3 million in net losses in just the first quarter of 2026, while holding $5.8 million in cash at quarter-end.
The company says the new capital will fund clinical trials, including planned Phase 3 activities. But $2.65 million before fees won't sustain a Phase 3 program in oncology. Management itself acknowledges "substantial doubt" about its ability to continue as a going concern. For existing shareholders, the math is brutal: the stock must now rise roughly 520% just to revisit last week's price.